Ibrutinib for relapsed mantle cell lymphoma after standard first line therapy and ASCT is efficacious but does not overcome the impact of POD24 - a retrospective study from the LWP-EBMT

Export metadata

Statistics

Number of document requests

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Author:Claire Burney, Stephen Robinson, Ariane Boumendil, Hervé Finel, Irma Khvedelidze, Hannah Hunter, Xavier Poire, Bruno Lioure, Karl S Peggs, Robin Foà, Srinivas Pillai, Tom Van Meerten, Juan Jose Bargay, Christoph SchmidORCiDGND, Vergote Vibeke, Arnold Ganser, Luca Castagna, Ghulam J. Mufti, Silvia Montoto
Frontdoor URLhttps://opus.bibliothek.uni-augsburg.de/opus4/98336
URL:https://ashpublications.org/blood/article/134/Supplement_1/701/426504/Ibrutinib-for-Relapsed-Mantle-Cell-Lymphoma-after
ISSN:0006-4971OPAC
ISSN:1528-0020OPAC
Parent Title (English):Blood
Publisher:American Society of Hematology
Place of publication:Washington
Type:Article
Language:English
Year of first Publication:2019
Release Date:2022/09/28
Tag:Cell Biology; Hematology; Immunology; Biochemistry
Volume:134
Issue:Supplement 1
First Page:701
DOI:https://doi.org/10.1182/blood-2019-123442
Institutes:Medizinische Fakultät
Medizinische Fakultät / Universitätsklinikum
Medizinische Fakultät / Lehrstuhl für Innere Medizin mit Schwerpunkt Hämatologie und Onkologie
Medizinische Fakultät / Professur für Transplantation und Zelltherapieforschung